SCHEMBL3022829

SCHEMBL3022829

O=S(=O)(c1cc(C(F)(F)F)ccc1Cl)C1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR6 P50406 2/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CTSS P25774 4/20 0.35
CTSL P07711 2/20 0.35
RAB9A P51151 1/20 0.35
CNR1 P21554 2/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
SOS1 Q07889 1/20 0.34
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
LDHA P00338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010474 0.92 MEN1 (0.41) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3019044 0.91 CACNA1G (0.36) ALDH1A1TSHRKMT2AL3MBTL1SMN1; SMN2
SCHEMBL3006245 0.90 MEN1 (0.40) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3021689 0.89 MEN1 (0.39) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3012889 0.89 ALDH1A1 (0.39) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3015184 0.89 ALDH1A1 (0.47) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3003881 0.89 MEN1 (0.41) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3014353 0.88 KMT2A (0.38) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL3002000 0.88 MEN1 (0.38) MEN1ALDH1A1TSHRKMT2AATM
SCHEMBL2998651 0.87 CTSS (0.40) MEN1ALDH1A1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885ALDH1A1 3510/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.